Angus Sinclair
Chief Scientific Officer LabGenius Therapeutics
Seminars
Monday 8th June 2026
Engineering Highly Selective T-Cell Engagers for Solid Tumours: Overcoming On-Target, Off-Tumour Toxicity Through Avidity-Driven Design
5:00 pm
- Addressing on-target, off-tumour toxicity in solid-tumour TCEs by exploiting avidity-driven selectivity against tumour-associated antigens such as Nectin-4
- Demonstrating robust translational performance with rich in vitro and in vivo datasets, including dose-response efficacy and complete tumour regression in mouse models
- Advancing next-generation formats by applying multispecific design principles, including logic-gated approaches, to improve therapeutic windows
